DRAK1 Antibody Blocking Peptide

• Reactivity: Hu
• Applications: AC
• Concentration: 0.2 mg/ml

DRAK1 Antibody Blocking Peptide Summary

• Description: A blocking peptide containing 15 amino amino terminus of human DRAK1.

  Source: Synthetic

  (Accession #: Q9UEE5)

• Source: Synthetic
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: STK17A
• Purity: N/A

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NBP1-76896.
  
  For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin.
• Preservative: 0.02% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: N/A

Alternate Names for DRAK1 Antibody Blocking Peptide

• DAP kinase-related apoptosis-inducing protein kinase 1
• DRAK1
• DRAK1death-associated protein kinase-related 1
• EC 2.7.11.1
• serine/threonine kinase 17a (apoptosis-inducing)
• serine/threonine kinase 17a
• serine/threonine-protein kinase 17A
• STK17A

Background

DRAK1 is a member of the DAP kinase-related apoptosis-inducing protein kinase family and encodes an autophosphorylated nuclear protein with a protein kinase domain. The protein has apoptosis-inducing activity.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: STK17A